Petar M Seferović, Andrew J S Coats, Piotr Ponikowski, Gerasimos Filippatos, Martin Huelsmann, Pardeep S Jhund, Marija M Polovina, Michel Komajda, Jelena Seferović, Ibrahim Sari, Francesco Cosentino, Giuseppe Ambrosio, Marco Metra, Massimo Piepoli, Ovidiu Chioncel, Lars H Lund, Thomas Thum, Rudolf A De Boer, Wilfried Mullens, Yuri Lopatin, Maurizio Volterrani, Loreena Hill, Johann Bauersachs, Alexander Lyon, Mark C Petrie, Stefan Anker, Giuseppe M C Rosano
Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and associated with considerable morbidity and mortality. Significant advances have recently occurred in the treatment of T2DM, with evidence of several new glucose-lowering medications showing either neutral or beneficial cardiovascular effects. However, some of these agents have safety characteristics with strong practical implications in HF [i.e. dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose co-transporter type 2 (SGLT-2) inhibitors]...
February 2020: European Journal of Heart Failure